Skip to main content

Table 2 Clinical data and laboratory tests in non-decreased and decreased group

From: Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis

Characteristics

Non-decreased (n = 82)

Decreased (n = 45)

p value

Age

53.68 ± 10.32

59.16 ± 11.87

0.008

Sex

  

0.098

 Male (%)

70 (85.4)

33 (73.3)

 

 Female (%)

12 (14.6)

12 (16.7)

 

Etiology of cirrhosis

  

0.745

 Alcoholics (%)

48 (58.5)

25 (55.6)

 

 Non-alcoholics (%)

34 (41.5)

20 (44.4)

 

Reasons of use

  

0.008

 Bleeding control (%)

58 (70.7)

41 (91.1)

 

 Hepatorenal syndrome (%)

24 (29.3)

4 (8.9)

 

Infusion of albumin

  

0.203

 Yes (%)

33 (40.2)

13 (28.9)

 

 No (%)

49 (59.8)

32 (71.1)

 

Cumulative dose of Terlipressin (mg)

15.38 ± 1.14

15.29 ± 4.08

0.914

Amount of hydration (L)

4.21 ± 1.99

4.70 ± 2.20

0.200

Amount of sodium infused (mEq)

313.14 ± 267.04

304.29 ± 320.97

0.864

Total bilirubin (0 ~ 1.2 mg/dL)

7.41 ± 9.72

3.33 ± 4.62

0.009

Albumin (3.4 ~ 4.8 g/dL)

2.61 ± 0.46

2.74 ± 0.54

0.164

Creatinine (0.6 ~ 1.2 mg/dL)

1.88 ± 1.75

1.20 ± 0.83

0.003

Potassium (mmol/L)

4.60 ± 1.03

4.33 ± 0.88

0.132

Hemoglobin (13 ~ 17 g/dL)

9.19 ± 2.47

9.06 ± 2.20

0.758

*PT (0.8 ~ 1.2 *INR)

1.83 ± 0.61

1.70 ± 0.62

0.253

*MELD score

21.07 ± 11.05

15.60 ± 9.52

0.004

*MELD-Na

25.95 ± 18.92

14.64 ± 11.46

0.000

Child-Pugh score (6 ~ 18)

9.24 ± 2.02

8.09 ± 2.64

0.013

Initial sodium (135 ~ 145 mmol/L)

131.96 ± 6.84

137.84 ± 3.56

0.000

Lowest sodium (135 ~ 145 mmol/L)

131.30 ± 6.58

128.73 ± 5.19

0.017

  1. *PT, Prothrombin time; INR, International normalized ratio; MELD, Model for end-stage liver disease.